New drug combo tested to control blood cancers in First-Time patients
NCT ID NCT03919175
Summary
This study tested a two-drug combination as the first treatment for people newly diagnosed with certain slow-growing blood cancers called follicular lymphoma or marginal zone lymphoma. The goal was to see if adding the experimental drug umbralisib to the approved drug rituximab could better control the cancer. The trial was stopped early after enrolling 18 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconness Medical Center
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.